Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Goldman Sachs downgrades Fevertree to 'sell'

(Sharecast News) - Goldman Sachs downgraded Fevertree to 'sell' from 'neutral' on Tuesday and cut the price target to 1,050p from 1,075p. The bank said it expects the posh tonic maker to deliver 6.2% reported sales growth in FY24, below consensus at +7.3% and company guidance at +8%.

"In light of moderating Nielsen data and ongoing Spirits demand normalisation, we expect +15.5% organic sales growth in the US, below consensus at +17%," GS said.

"We are also cautious on the UK growth (+0.3% GSe versus +1.9% consensus), where we note an ongoing softness of Fevertree in the off-trade and weak performance of Cocktail Bar channel."

GS said that while the company's earnings per share growth algorithm of 18% between FY25-27e remains attractive, it is mostly driven by easing cost of goods sold rather than underlying top-line growth acceleration.

At 1120 BST, the shares were down 4.3% at 1,129p.

Share this article

Related Sharecast Articles

FY turnover and profits grow at Arcontech
(Sharecast News) - Software firm Arcontech said on Monday that full-year pre-tax profits and turnover were both anticipated to come in ahead of current market expectations.
Brave Bison pre-tax profits grow in H1
(Sharecast News) - Digital advertising company Brave Bison said on Monday that adjusted pre-tax profits had grown in the six months ended 30 June, leaving it confident of its ability to meet current market expectations for FY24.
Fonix Mobile ends year ahead of market expectations
(Sharecast News) - Mobile payments and messaging technology provider Fonix Mobile reported a strong full-year financial performance in a trading update on Monday.
Tristel flags forecast-busting full-year results
(Sharecast News) - Infection prevention products manufacturer Tristel released a robust trading update for the year ended 30 June on Monday, with revenues and pre-tax profits surpassing market expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.